deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02136797

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions CMV Infection Persistent CMV Viremia
Interventions CMVpp65 Specific T-cells
Updated 16 times since 2017 Last updated: Sep 23, 2024 Started: May 8, 2014 Primary completion: Feb 8, 2024 Completion: Feb 8, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02136797, this PHASE2 trial focuses on CMV Infection and Persistent CMV Viremia and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 16 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~Dec 2019 · 10 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshot

Change History

16 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  5. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

  2. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  7. Jul 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  9. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations